|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||8.50 - 8.75|
|52-week range||6.00 - 13.25|
|PE ratio (TTM)||N/A|
|Earnings date||21 Sep 2017 - 22 Sep 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||86.00|
OXFORD, England--(BUSINESSWIRE)-- E-THERAPEUTICS PLC (“e-Therapeutics” or the “Company”) e-Therapeutics plc (AIM: ETX): Upon the completion of Ray Barlow’s first three months as CEO of e-Therapeutics, ...
e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that further to the Company’s announcement on 9 January 2017, Dr. Raymond Barlow has today assumed his position as Chief Executive Officer. Dr. Barlow, aged 48, was previously Executive Director of Corporate Development at Amgen Inc. based in Switzerland.